Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (219)	2/24/1998 10:46:00 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 3559

<Hope REGN brooded collaboration with PCOP (they are full of screening candidates).> Miljenko - Could you explain this statement a bit further? I couldn't understand what you meant. Thanks for contributing to the thread. I thought that Rick wrote a good article on angiogenesis and what some companies have going. Could you comment on PCOP's combinatorial library? Jim

To: Miljenko Zuanic who wrote (219)	2/25/1998 12:28:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3559

MZ: Ooooh, you know something that I don't! What's the link between RGD and Tie-2? I've missed something. >>Regards the Progenitor, can they perform target validation for Del-1, or their work is oriented toward basic science (genomic) and discovery collaboration with research institutions?<< Don't know yet. Sorta looked like the embryology was from Tokyo Women's. The collaborators at Vanderbilt are top-notch, and, if you look closely at enough Medline searches, you'll even find a connection between the Vanderbilt PI and an old piece of work with the Ohio University stuff (yolk sac-derived EC). Rick